Clinical scoring system consisting of clinical symptoms, signs, and several provocation maneuver tests for the diagnosis of PMS (Table 1). They suggest using a score of 8 or greater on the scale from 0 to 12 to confirm the diagnosis of PMS. The sensitivity and specificity of the score were 96.4% and 100%, respectively, whereas the positive predictive value was 100% and the negative predictive value 86.9%.

Electrophysiological tests and imaging studies add certainty to the diagnosis of PMS. The recently introduced neuroradiological technique, magnetic resonance neurography (MRN), is useful for the diagnosis of peripheral neuropathy by directly showing the nerve anatomy. MRI performed with higher structural resolution and improved nerve lesion contrast to assess intrinsic nerve disorders was termed MRN by Filler et al in the early 1990s. Heavily T2-weighted sequences with fat saturation were found to be most advantageous and an increase in the intraneural T2-weighted signal was identified to be a highly sensitive. MRN has been used to evaluate unexplained chronic sciatica and has led to identification of various changes relating to the piriformis muscle and sciatic nerve.

For the treatment of PMS, piriformis muscle injection is usually offered as part of multimodal therapy, and ultrasound-guided injection improves the accuracy of injection. The response to injections of lidocaine and steroid can be immediate but may be of short duration. Several randomized, controlled trials demonstrated better efficacy with botulinum toxin type A (BTX-A) over both placebo and corticosteroid plus lidocaine. BTX-A seems to be a logical treatment choice, because it reverses the presumed underlying pathophysiology of PMS by leading to muscle weakness, atrophy, and relief of sciatic nerve compression. Here we describe 2 cases of sciatic nerve signal change under the hypertrophied piriformis muscle confirmed by MRN and the change in imaging findings after BTX-A injection to the piriformis muscle.

### CASE REPORTS

#### CASE 1

A 58-year-old man with no particular medical history except hypertension visited the hospital with a complaint of severe left buttock pain and tingling sensations in the left lower extremity. The symptoms had developed about 2 months prior and had worsened progressively. A week before visiting the hospital, he had undergone a left fourth lumbar partial hemilaminectomy based on a diagnostic impression of lumbar radiculopathy in other clinic, but the pain and numbness were not improved. The symptoms worsened, and when the patient visited the hospital, he could not sit at all due to buttock pain and could only walk 4 to 5 m with minimal assistance of another person. The pain was aggravated by sitting and standing, with a
eral knee.

compared with the right side and swelling of the left sciatic nerve with bright signal intensity were observed (Fig. 1). With MRN findings, PMS was diagnosed more conclusively. Hypertrophied piriformis muscle was targeted for treatment. BTX-A (Botox®) 100 unit was injected into the left piriformis muscle under ultrasound guidance. The lowest dose with proven therapeutic effect in previous studies was selected to minimize the possible complication. A 4-ml injection containing 100 unit of BTX-A in preserve-free normal saline was administrated via the peppering technique. The patient was tolerable through the procedure, and there was no adverse or unanticipated event. Ethical approval was not necessary since the procedure was performed for therapeutic purpose and the clinical effect of procedure has already been proven. Three days later, the patient could sit down, and the SLRT was improved to 70 degrees. Seven days after the injection, the patient could sit for >30 min and walk independently 300 to 400 m without pain; additionally, the SLRT was improved to 80 degrees. Pain was decreased to VAS 3, and the prolongation of the H-reflex in the FAIR position was improved to 1.05 ms in the follow-up study performed 1 month after the injection (Table 2). Follow-up pelvic MRN taken 1 month after the BTX-A injection, when compared with the diagnostic MRN, indicated equivocal decrease of left piriformis muscle volume and significant decrease of left sciatic nerve swelling (Figures 1 and 2). At the 6th month follow-up after the treatment, the VAS score was 4. The pain gradually exacerbated and by the 9th month after the treatment, the VAS score was 5 but the patient did not need repeat injection since the improved functional status was maintained.

### TABLE 1. Proposal for a Clinical Scoring System for the Diagnosis of Piriformis Muscle Syndrome

| Criteria                                                                 | Point |
|-------------------------------------------------------------------------|-------|
| Unilateral or bilateral buttock pain with fluctuating periods without pain throughout the course of the day | 1     |
| No lower back pain                                                      | 1     |
| Axial spinal palpation painless (L2 to S1)                              | 1     |
| Negative Lase`gue’s maneuver                                             | 1     |
| Seated position (often for a prolonged period) triggering                | 1     |
| Sciatic pain with fluctuating periods without pain throughout the course of the day | 1     |
| Buttock pain next to the projection of the piriformis muscle reproduced by |       |
| Stretching maneuvers (FAIR, Freiberg, HCLK)                             | 1     |
| Contraction resisted manoeuvres (Beatty)                                | 1     |
| Palpation                                                               | 1     |
| Sciatic pain (L5, S1, or truncal sciatic area) reproduced                | 1     |
| by the extension of clinical maneuvers (several tens of seconds)         |       |
| Stretching                                                              | 1     |
| Resisted contraction                                                    | 1     |
| Absence of perineal irradiation                                         | 1     |
| Total                                                                   | 12    |

FAIR = Flexion-adduction-internal rotation, HCLK = heel contralateral knee.

visual analogue scale (VAS) score of 8. During the physical examination, there was no weakness of the bilateral lower extremities, but the straight leg-raising test (SLRT) showed 40 degrees of limitation on the left side. Patrick sign and Lasègue sign were negative.

The clinical scoring system for the diagnosis of PMS yielded a score of 10. Severe local tenderness was detected at the left piriformis muscle area, and hypesthesia was reported on the posterolateral aspect of the left thigh. There was no history of blunt trauma, but through detailed history-taking we learned that the patient usually put his wallet in the left rear pocket of his pants. The left tibial H-reflex showed 5.66 ms prolongation by the FAIR test compared with the neutral position (Table 2). A pelvic MRN was performed at 2 months after the symptom onset. Hypertrophy of the left piriformis muscle compared with the right side and swelling of the left sciatic nerve with bright signal intensity were observed (Fig. 1). With MRN findings, PMS was diagnosed more conclusively. Hypertrophied piriformis muscle was targeted for treatment. BTX-A (Botox®) 100 unit was injected into the left piriformis muscle under ultrasound guidance. The lowest dose with proven therapeutic effect in previous studies was selected to minimize the possible complication. A 4-ml injection containing 100 unit of BTX-A in preserve-free normal saline was administrated via the peppering technique. The patient was tolerable through the procedure, and there was no adverse or unanticipated event. Ethical approval was not necessary since the procedure was performed for therapeutic purpose and the clinical effect of procedure has already been proven. Three days later, the patient could sit down, and the SLRT was improved to 70 degrees. Seven days after the injection, the patient could sit for >30 min and walk independently 300 to 400 m without pain; additionally, the SLRT was improved to 80 degrees. Pain was decreased to VAS 3, and the prolongation of the H-reflex in the FAIR position was improved to 1.05 ms in the follow-up study performed 1 month after the injection (Table 2). Follow-up pelvic MRN taken 1 month after the BTX-A injection, when compared with the diagnostic MRN, indicated equivocal decrease of left piriformis muscle volume and significant decrease of left sciatic nerve swelling (Figures 1 and 2). At the 6th month follow-up after the treatment, the VAS score was 4. The pain gradually exacerbated and by the 9th month after the treatment, the VAS score was 5 but the patient did not need repeat injection since the improved functional status was maintained.

### TABLE 2. Change in H-reflex Values Before and After Treatment

| Side | Initial | 1 Month After Treatment | Difference Between Initial and 1 Month After Treatment |
|------|---------|-------------------------|-------------------------------------------------------|
| Case 1 | Affected | 1.86 | 1.05 | 0.81 |
|       | Unaffected | 0.64 | 0.50 | 0.14 |
| Case 2 | Affected | 5.66 | 0.10 | 5.56 |
|       | Unaffected | 1.32 | 0.95 | 0.37 |

* Differences in H-reflex between neutral and FAIR position. FAIR = flexion, adduction, and internal rotation.
MRN was performed with impression of the PMS. Hypertrophy of the left piriformis muscle with slight swelling of the lumbo-sacral plexus anterior to the muscle was observed, suggesting the possibility of PMS. BTX-A (Botox) 100 unit was injected into the left piriformis muscle under ultrasound guidance. The lowest dose with proven therapeutic effect in previous studies was selected to minimize the possible complication.8 A 4-ml injection containing 100 unit of BTX-A in preserve-free normal saline was administrated via the peppering technique. Ethical approval was not necessary since the procedure was performed for therapeutic purpose and the clinical effect of procedure has already been proven. The patient was tolerable through the procedure, and there was no adverse or unanticipated event. Three days after the injection, the patient could bear his weight on the left side, and the lumbar hyper-extension seen in the swing phase and gait endurance were improved. A week after the injection, he could walk indoors > 300 m without a walking aid such as a wheelchair or cane. Two months after the injection, he could walk outside independently > 500 m. The prolongation of the H-reflex in the FAIR position was improved to 0.10 ms in the follow-up study performed 1 month after the injection (Table 2). Compared with the diagnostic MRN, a marked decreased of the left piriformis muscle volume and significant decrease of left sciatic nerve swelling were noted in the follow-up pelvic MRN taken 2 months after BTX-A injection (Figures 3 and 4). Four months after the injection, pain completely resolved and the patient had no limitation on walking or other activities of daily living. The improved state was maintained until the 6th month after injection and did not need more follow-up.

**DISCUSSION**

PMS is an underdiagnosed cause of buttock and leg pain that can be difficult to treat. There is no gold standard in diagnosing PMS. Physical examination may reveal signs of sciatic nerve compression.10 The diagnostic value of electrophysiological tests can be improved by stressing the muscle in flexion, adduction, and internal rotation (the FAIR test). A prolongation of 1.86 ms in the FAIR test is an electrophysiological criterion for diagnosing PMS. Imaging modalities such as plain radiography, computed tomography, and ultrasound add certainty in diagnosis. MRI is increasingly being selected over other imaging modalities. MRI of the nerves, also known as MRN, is increasingly being used as a noninvasive means of diagnosing peripheral nerve disease. MRN directly shows the nerve anatomy and is accomplished by using a combination of pulse sequences allowing detection of changes in both nerve signal and architecture.5 MRN findings allow differentiation of neuropathic conditions related to entrapment, trauma,iatrogenic injury, extrinsic mass effect, and tumors/tumor-like lesions of the nerves. Chhabra and colleagues reported the optimal cutoff value of nerve/vessel signal intensity ratio for predicting sciatic neuropathy was 0.89, with sensitivity of 94.1% and specificity of 90.2% (area under the ROC curve, 0.963; 95% confidence interval, 0.886–0.994).7 On MRN...
images, a normal nerve has intermediate signal intensity similar to muscle on T1-weighted images and intermediate to minimally increased signal intensity on T2-weighted images, depending on the amount of endoneurial fluid and background fat suppression. When the nerve sustains an injury, normal endoneurial fluid protected by an intact perineurial blood-nerve

| Visit to the clinic | Left buttock pain |
|---------------------|-------------------|
| 1 week before the visit | Left L4 hemilaminectomy |
| 2 months before the visit | Based on a impression of lumbar radiculopathy |

FIGURE 2. Timeline of Case 1.

FIGURE 3. Pelvic magnetic resonance neurography of Case 2. Axial T2-weighted cross-section taken before the treatment (A) and 2 months after the treatment (B). Coronal T2-neurography cross-section taken before the treatment (C) and 2 months after the treatment (D). Hypertrophy of the left piriformis muscle (asterisk) is apparent (A, C), and a marked decreased of the left piriformis muscle (asterisk) volume is noted 2 months after the injection (B, D). Slight swelling of the sciatic nerve (white arrow) is observed (C). After the injection, significant decrease of left sciatic nerve (white arrow) swelling was noted (D).
barrier becomes altered, and the nerve signal demonstrates higher intensity on T2-weighted images due to proximal accumulation of the endoneurial fluid, vascular congestion, and distal Wallerian degeneration.8,9

There are few studies using MRN in PMS. Lewis et al used MRN to image the lumbosacral plexus and sciatic nerve and demonstrated high signal intensity of the sciatic nerve mostly at the sciatic notch or at the level of the piriformis muscle.2 These authors utilized MRN to diagnose PMS and determine the method of treatment, but they did not confirm changes to the sciatic nerve after treatment.

PMS usually responds to conservative treatments, but when patients fail to respond to simple conservative therapy, interventional modalities are considered. Injections of local anesthetics, steroid, or botulinum toxin into the piriformis muscle are generally performed.4 Botulinum toxin injection is more effective in treating PMS than either triamcinolone acetonide and lidocaine injections or placebo injections.6 With ultrasound guidance, the accuracy of injections increases. It was validated in a cadaver study, suggesting an accuracy of 95%.10 Blunk verified the accuracy of needle placement under ultrasound guidance via MRI in human subjects.11 Based on these reports, we injected botulinum toxin into the piriformis muscle under ultrasound guidance.

The clinical effects of ultrasonoud-guided botulinum toxin injection are already widely known12–15 but changes to the anatomical structures after the injection have been confirmed in few studies. Al-Al-Shaikh et al used MRI to evaluate changes in piriformis muscle morphology after treatment with botulinum toxin injections and the treated piriformis muscle demonstrated a reduction in thickness and volume and an increase in fatty infiltration compared to the normal contralateral muscle.15 Although the results indicated the effect of botulinum toxin, they compared changes to the treated muscle with the contralateral side, not the identical muscle before treatment. Fanucci performed MRI before and 3 months after botulinum toxin injection in PMS patients and the denervation process of the piriformis muscle or only atrophy of the treated muscle was detected.16

Previous studies of MRN and BTX-A injection in PMS demonstrated changes in the piriformis muscle but did not describe changes in the sciatic nerve itself. In this study, although it is a limited case series, we describe the changes to the nerve morphology before and after the BTX-A injection treatment in addition to other anatomical structures. In these patients, MRN revealed increased signal of the sciatic nerve under the hypertrophied piriformis muscle, supporting the suspicion of PMS arising from physical examination. We then confirmed that the swelling of the sciatic nerve and volume of the piriformis muscle were decreased on follow-up MRN after the BTX-A injection.

Ultrasound-guided BTX-A to the piriformis muscle achieved definite clinical improvement and normalization of electrophysiological test results. Additionally, it was found via MRN that BTX-A injection can cause resolution of signal change and swelling of sciatic nerve secondary to atrophy of the piriformis muscle. MRN can be an effective tool for diagnosis as well as to confirm the response to treatment in PMS.

REFERENCES

1. Lang AM. Botulinum toxin type B in piriformis syndrome. Am J Phys Med Rehabil. 2004;83:198–202.
2. Lewis AM, Layzer R, Engstrom JW, et al. Magnetic resonance neurography in extraspinal sciatica. Arch Neurol. 2006;63:1469–1472.
3. Filler AG, Howe FA, Hayes CE, et al. Magnetic resonance neurography. Lancet. 1993;341:659–661.
4. Howe FA, Filler AG, Bell BA, et al. Magnetic resonance neurography. *Magn Reson Med.* 1992;28:328–338.

5. Stoll G, Bendszus M, Perez J, et al. Magnetic resonance imaging of the peripheral nervous system. *J Neurol.* 2009;256:1043–1051.

6. Koltzenburg M, Bendszus M. Imaging of peripheral nerve lesions. *Curr Opin Neurol.* 2004;17:621–626.

7. Chhabra A, Chalian M, Soldatos T, et al. 3-T high-resolution MR neurography of sciatic neuropathy. *Am J Roentgenol.* 2012;198:W357–364.

8. Husarik DB, Saupe N, Pfirrmann CW, et al. Elbow nerves: MR findings in 60 asymptomatic subjects—normal anatomy, variants, and pitfalls. *Radiology.* 2009;252:148–156.

9. Petchprapa CN, Rosenberg ZS, Sconfienza LM, et al. MR imaging of entrapment neuropathies of the lower extremity. Part 1: The pelvis and hip. *Radiographics.* 2010;30:983–1000.

10. Finnoff JT, Hurdle MF, Smith J. Accuracy of ultrasound-guided versus fluoroscopically guided contrast-controlled piriformis injections: a cadaveric study. *J Ultrasound Med.* 2008;27:1157–1163.

11. Blunk JA. MRI verification of ultrasound-guided infiltrations of local anesthetics into the piriformis muscle. *Pain Med.* 2013.

12. Fishman LM, Anderson C, Rosner B. BOTOX and physical therapy in the treatment of piriformis syndrome. *Am J Phys Med Rehabil.* 2002;81:936–942.

13. Fishman LM, Konnoth C, Rozner B. Botulinum neurotoxin type B and physical therapy in the treatment of piriformis syndrome: a dose-finding study. *Am J Phys Med Rehabil.* 2004;83:42–50 quiz 51-43.

14. Yoon SJ, Ho J, Kang HY, et al. Low-dose botulinum toxin type A for the treatment of refractory piriformis syndrome. *Pharmacotherapy.* 2007;27:657–665.

15. Al-Al-Shaikh M, Michel F, Parratte B, et al. An MRI evaluation of changes in piriformis muscle morphology induced by botulinum toxin injections in the treatment of piriformis syndrome. *Diagn Intervent Imaging.* 2014.

16. Fanucci E. CT-guided injection of botulinic toxin for percutaneous therapy of piriformis muscle syndrome with preliminary MRI results about denervative process. *Eur Radiol.* 2001;11:2543–2548.